Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Making the Built Environment Safe After COVID

The COVID-19 pandemic has forced countries and companies around the world to think deeply about the health and safety of their people. It is morally and economically essential that, as employees begin to emerge from lock-downs, they can be confident that their offices and places of work are equipped to minimize the risks of infection….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The COVID-19 pandemic has forced countries and companies around the world to think deeply about the health and safety of their people. It is morally and economically essential that, as employees begin to emerge from lock-downs, they can be confident that their offices and places of work are equipped to minimize the risks of infection.

The bad news is that our built environment is not nearly as effective as it could be in keeping people safe, healthy and productive. The good news is that the technology we need to solve this problem already exists and is widely used in laboratories, hospitals, and other critical environments.

Research has shown that buildings with poor indoor air quality (inadequate ventilation, filtration, or humidity control) can promote the spread of airborne bacterial or viral infections.

This is not a new phenomenon. In 1976 there was an outbreak of Legionnaire’s Disease in Philadelphia, caused by bacterial infiltration of a hotel air conditioning system. That outbreak led to a revolution in the design and regulation of HVAC systems. Today, the evidence of airborne spread of the novel coronavirus in poorly ventilated buildings calls for a similar re-examination of how we manage indoor environmental quality.

As Dr. Joseph Allen of the Harvard Chan School of Public Health said recently, “Your building manager has more impact on your health than your doctor.”

Managing the built environment to control humidity, ventilation and optimal filtration has long been much harder than it should be. The data show that many systems do not meet the needs of building occupants because of poor design, maintenance or operation. Fortunately, in recent years we have seen great improvement on these fronts in critical environments such as hospitals, vivariums and laboratories, with measurably better results for health and the bottom line.

Higher outside air change rates, matching airflows to occupancy, and improved filtration methods can reduce the concentration of airborne virus particles. Accurate measurement and control systems can maintain proper indoor humidity, mitigating the spread of the novel coronavirus and other RNA viruses, and additional measures such as UV coil treatment can further reduce the potential for viral and bacterial transmission in air streams. Better data management protocols allow building managers to improve efficiency and effectiveness by targeting air-quality measures exactly where they are needed.

The Smart Labs program, created by UC Irvine with support from Aircuity, and subsequently adopted by the University of Pennsylvania, Michigan State, Arizona State, and Eli Lilly, has proven that these advanced technologies make buildings more efficient, safer, and smarter than they were previously. Those technologies and related best practices can now be put to wider use in all kinds of environments, through both new construction and the retrofit of existing buildings.

People are very rightly demanding that, as they return to work, they do so in buildings that are as healthy as possible. We have all the necessary tools to give them that assurance. We only need to recognize that, from now on, all environments are critical environments, and that schools, offices, and other buildings can and should be made as safe and healthy as the best hospitals or laboratories are at present. Ensuring optimal indoor environmental quality thus has a vital part to play in the immediate recovery from the pandemic, by minimizing the risks of indoor virus transmission and cutting exposure to the chemicals being used in enhanced cleaning regimes. It will build employee confidence and speed economic recovery.

Implementation of such measures requires investment, but in the new post-pandemic era it will be an unavoidable requirement for doing business. Fortunately, these Smart IEQ systems deliver additional benefits including environmental sustainability as well as support for employee (or student) general wellness, productivity, and cognitive function, resulting in an excellent return on investment.

To ensure that all buildings are healthy, productive, and safe we need a comprehensive strategy, built upon a solid foundation of existing and proven technology, and drawing on local and international expertise. Such a strategy will ensure that, instead of spreading infections and distress, the built environment actively helps its inhabitants to achieve their full potential. The disruption of the present crisis, while we are re-thinking some fundamental tenets of how we live and work together, is the perfect time to begin.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512